HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it successfully obtained the rights to nine new drugs under an agreement its subsidiary, Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang"), signed with Shandong Medicine Research & Development Institute.
Under the terms of the agreement, China Sky One obtained all rights to
nine new drugs in consideration for a cash payment of RMB 15 million (US
$2.2 million; 1 RMB = $0.14 US dollars). Popular in the rural areas of
China, the nine new drugs have passed all clinical trials required by the
State Food and Drug Administration (SFDA) in China, and have also been
approved by the SFDA for production and sale.
-- Oyster Shell Calcium Granules and Oyster Shell Calcium Tablets: for
the treatment of calcifames and osteoporosis, especially for
children, the elderly and pregnant and nursing women;
-- Loquat Syrup: an expectorant for the treatment of tussis and
-- Flos Lonicerae Syrup: for the treatment coughs, colds, fever and
-- Sedative Bolus: for the treatment of depression and insomnia;
-- Compound Paracetamol and Diphenhydramine Hydrochloride Tablets: for
the treatment of fever, headaches and perennial allergic rhinitis;
-- Compound Tablet of Red Sage Root: for activating blood circulation
to dissipate blood stasis and angina;
-- Compound Aminopyrine Tablets: for the treatment of fever and mild or
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved